Boffa M B, Wang W, Bajzar L, Nesheim M E
Department of Biochemistry, Queen's University, Kingston, Ontario, Canada.
J Biol Chem. 1998 Jan 23;273(4):2127-35. doi: 10.1074/jbc.273.4.2127.
Thrombin-activable fibrinolysis inhibitor (TAFI) is a human plasma zymogen similar to pancreatic pro-carboxypeptidase B. Cleavage of the zymogen by thrombin/thrombomodulin generates the enzyme, activated TAFI (TAFIa), which retards fibrin clot lysis in vitro and likely modulates fibrinolysis in vivo. In the present work we stably expressed recombinant TAFI in baby hamster kidney cells, purified it to homogeneity from conditioned serum-free medium, and compared it to plasma TAFI (pTAFI) with respect to glycosylation and kinetics of activation by thrombin/thrombomodulin. Although rTAFI is glycosylated somewhat differently than pTAFI, cleavage products with thrombin/thrombomodulin are indistinguishable, and parameters of activation kinetics are very similar with kcat = 0.55 s-1, K(m) = 0.54 microM, and Kd = 6.0 nM for rTAFI and kcat = 0.61 s-1, K(m) = 0.55 microM, and Kd = 6.6 nM for pTAFI. The respective TAFIa species also were prepared and compared with respect to thermal stability and enzymatic properties, including inhibition of fibrinolysis. The half-life of both enzymes at 37 degrees C is about 10 min, and the decay of enzymatic activity is associated with a quenching (to approximately 62% of the initial value at 60 min) of the intrinsic fluorescence of the enzyme. Stability was highly temperature-dependent, which, according to transition state theory, indicates both high enthalpy and entropy changes associated with inactivation (delta Ho++ approximately equal to 45 kcal/mol and delta So++ approximately equal to 80 cal/mol/K). Both species of TAFIa are stabilized by the competitive inhibitors 2-guanidinoethylmercaptosuccinic acid and epsilon-aminocaproic acid. rTAFIa and pTAFIa are very similar with respect to kinetics of cleavage of small substrates, susceptibility to inhibitors, and ability to retard both tPA-induced and plasmin-mediated fibrinolysis. These studies provide new insights into the thermal instability of TAFIa, a property which could be a significant regulator of its activity in vivo; in addition, they show that rTAFI and rTAFIa are excellent surrogates for the natural plasma-derived species, a necessary prerequisite for future studies of structure and function by site-specific mutagenesis.
凝血酶激活的纤维蛋白溶解抑制剂(TAFI)是一种与胰腺羧肽酶原B相似的人血浆酶原。凝血酶/血栓调节蛋白对该酶原的切割产生了酶,即活化的TAFI(TAFIa),它在体外可延缓纤维蛋白凝块的溶解,并可能在体内调节纤维蛋白溶解。在本研究中,我们在幼仓鼠肾细胞中稳定表达了重组TAFI,从无血清条件培养基中将其纯化至同质,并在糖基化以及凝血酶/血栓调节蛋白激活动力学方面将其与血浆TAFI(pTAFI)进行了比较。尽管rTAFI的糖基化与pTAFI略有不同,但凝血酶/血栓调节蛋白的切割产物无法区分,并且激活动力学参数非常相似,rTAFI的kcat = 0.55 s-1、K(m) = 0.54 μM、Kd = 6.0 nM,pTAFI的kcat = 0.61 s-1、K(m) = 0.55 μM、Kd = 6.6 nM。还制备了各自的TAFIa,并在热稳定性和酶学性质(包括对纤维蛋白溶解的抑制)方面进行了比较。两种酶在37℃时的半衰期约为10分钟,酶活性的衰减与酶的固有荧光猝灭(在60分钟时降至初始值的约62%)有关。稳定性高度依赖于温度,根据过渡态理论,这表明与失活相关的焓变和熵变都很高(ΔHo++约等于45 kcal/mol,ΔSo++约等于80 cal/mol/K)。两种TAFIa都可被竞争性抑制剂2-胍基乙基巯基琥珀酸和ε-氨基己酸稳定。rTAFIa和pTAFIa在小底物切割动力学、对抑制剂的敏感性以及延缓组织型纤溶酶原激活物(tPA)诱导的和纤溶酶介导的纤维蛋白溶解的能力方面非常相似。这些研究为TAFIa的热不稳定性提供了新的见解,这一特性可能是其在体内活性的重要调节因素;此外,它们表明rTAFI和rTAFIa是天然血浆来源物质的优秀替代物,这是未来通过位点特异性诱变进行结构和功能研究的必要前提。